Form 8-K - Current report:
SEC Accession No. 0000819050-22-000003
Filing Date
2022-02-02
Accepted
2022-02-02 07:37:19
Documents
17
Period of Report
2022-02-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bbi-20220202.htm   iXBRL 8-K 38421
2 EX-10.1 a202202028kex101.htm EX-10.1 412637
3 EX-99.1 a202202028kex991.htm EX-99.1 19944
7 bbi-20220202_g1.jpg GRAPHIC 6568
8 bbilogohra.jpg GRAPHIC 71984
9 carnalogoa.jpg GRAPHIC 5023
  Complete submission text file 0000819050-22-000003.txt   808672

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bbi-20220202.xsd EX-101.SCH 1909
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bbi-20220202_lab.xml EX-101.LAB 25154
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bbi-20220202_pre.xml EX-101.PRE 13055
11 EXTRACTED XBRL INSTANCE DOCUMENT bbi-20220202_htm.xml XML 11253
Mailing Address 5777 CENTRAL AVENUE SUITE 102 BOULDER CO 80301
Business Address 5777 CENTRAL AVENUE SUITE 102 BOULDER CO 80301 (720) 505-4755
Brickell Biotech, Inc. (Filer) CIK: 0000819050 (see all company filings)

EIN.: 930948554 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21088 | Film No.: 22581559
SIC: 2836 Biological Products, (No Diagnostic Substances)